Candida Bloodstream Infections and Associated Risk Factors in Pediatric Cardiac Intensive Care
Abstract
1. Introduction
2. Methods
Statistical Analyses
3. Results
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Van Der Linde, D.; Konings, E.E.; Slager, M.A.; Witsenburg, M.; Helbing, W.A.; Takkenberg, J.J.; Roos-Hesselink, J.W. Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. J. Am. Coll. Cardiol. 2011, 58, 2241–2247. [Google Scholar] [CrossRef] [PubMed]
- JaJacobs, J.P.; Jacobs, M.L.; Mavroudis, C.; Backer, C.L.; Lacour-Gayet, F.G.; Tchervenkov, C.I.; Franklin, R.C.G.; Béland, M.J.; Jenkins, K.J.; Walters, H.; et al. Nomenclature and databases for the surgical treatment of congenital cardiac disease: An updated primer and an analysis of opportunities for improvement. Cardiol. Young 2008, 18, 38–62. [Google Scholar] [CrossRef] [PubMed]
- Şanlı, K.; Arslantaş, E.; Ceylan, A.N.; Öncel, B.; Özkorucu, D.; Özkan Karagenç, A. Candidemia in Pediatric-Clinic: Frequency of Occurrence, Candida Species, Antifungal Susceptibilities, and Effects on Mortality (2020–2024). Diagnostics 2024, 14, 2343. [Google Scholar] [CrossRef] [PubMed]
- Sezgin Evim, M.; Tüfekçi, Ö.; Baytan, B.; Ören, H.; Çelebi, S.; Ener, B.; Üstün Elmas, K.; Yilmaz, Ş.; Erdem, M.; Hacimustafaoğlu, M.; et al. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis. Turk. J. Haematol. 2022, 39, 94–102. [Google Scholar] [CrossRef]
- Korulmaz, A.; Alakaya, M.; Erdoğan, S.; Arslanköylü, A.E.; Özgür, D.; Otağ, F. Mortality Risk Factors for Invasive Candidiasis in Pediatric Intensive Care Unit. Mikrobiyol. Bul. 2021, 55, 580–591. [Google Scholar] [CrossRef]
- Otto, W.R.; Green, A.M. Fungal infections in children with haematologic malignancies and stem cell transplant recipients. Br. J. Haematol. 2020, 189, 607–624. [Google Scholar] [CrossRef]
- Vasileiou, E.; Paisiou, A.; Tsipou, C.; Pourtsidis, A.; Galani, V.; Katzilakis, N.; Antoniadi, K.; Papakonstantinou, E.; Ioannidou, E.; Stiakaki, E.; et al. Candidemia in Children with Malignancies: Report from the Infection Working Group of the Hellenic Society of Pediatric Hematology-Oncology. J. Fungi 2020, 6, 276. [Google Scholar] [CrossRef]
- Pana, Z.D.; Roilides, E.; Warris, A.; Groll, A.H.; Zaoutis, T. Epidemiology of Invasive Fungal Disease in Children. J. Pediatr. Infect. Dis. Soc. 2017, 6, S3–S11. [Google Scholar] [CrossRef]
- Karaağaç, A.T.; Şavluk, Ö.F.; Yıldırım, A.İ. A 5-year analysis of Candida bloodstream infections in the paediatric cardiovascular surgery ICU of a tertiary care centre. Cardiol. Young 2023, 33, 301–305. [Google Scholar] [CrossRef]
- Matic, T.; Novak, M.; Braovac, D.; Vinkovic, M.; Cicak, A.M.; Milosevic, M.; Galic, S.; Cvitkovic, M.; Rubic, F.; Ille, V.; et al. Characteristics, Risk Factors and Predictors for Candidemia in the Pediatric Intensive Care Unit at the University Hospital Centre Zagreb in Croatia: A 9-Year Retrospective Study. Pediatr. Infect. Dis. J. 2021, 40, 981–986. [Google Scholar] [CrossRef]
- Mantadakis, E.; Pana, Z.D.; Zaoutis, T. Candidemia in children: Epidemiology, prevention and management. Mycoses 2018, 61, 614–622. [Google Scholar] [CrossRef] [PubMed]
- Kahan, Y.; Tope, S.G.; Ovadia, A.; Shpring, A.; Shatzman-Steuerman, R.; Sherman, G.; Barkai, G.; Mandelberg, A.; Armoni-Domany, K.; Tasher, D. Risk Factors Characteristics of Candidemia After Cardiac Surgery in Pediatric Patients in Central Israel. Pediatr. Infect. Dis. J. 2023, 42, 368–373. [Google Scholar] [CrossRef] [PubMed]
- Mermel, L.A.; Allon, M.; Bouza, E.; Craven, D.E.; Flynn, P.; O’Grady, N.P.; Raad, I.I.; Rijnders, B.J.; Sherertz, R.J.; Warren, D.K. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 49, 1–45. [Google Scholar] [CrossRef] [PubMed]
- Horn, D.L.; Neofytos, D.; Anaissie, E.J.; Fishman, J.A.; Steinbach, W.J.; Olyaei, A.J.; Marr, K.A.; Pfaller, M.A.; Chang, C.H.; Webster, K.M. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 2009, 48, 1695–1703. [Google Scholar] [CrossRef]
- Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 4th ed.; CLSI Document M27-A4; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017. [Google Scholar]
- Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Yeasts; CLSI M60-Ed2; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020. [Google Scholar]
- European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint Tables for Interpretation of MICs for Antifungal Agents; Version 10.0; European Committee on Antimicrobial Susceptibility Testing (EUCAST): Copenhagen, Denmark, 2020. [Google Scholar]
- Kumar, D.; Kumar, A.; Singh, S.; Tilak, R. Candidemia-induced pediatric sepsis and its association with free radicals, nitric oxide, and cytokine level in host. J. Crit. Care 2015, 30, 296–303. [Google Scholar] [CrossRef]
- Jaworski, R.; Irga, N.; Haponiuk, I.; Chojnicki, M.; Arlukowicz, E.; Steffek, M.; Sroka, M.; Gierat-Haponiuk, K.; Juscinski, J.; Palkowska, L.; et al. Candidemia in children after complex congenital heart defects surgery treated with caspofungin—Our own experience and a review of literature. Med. Sci. Monit. 2011, 17, H35–H39. [Google Scholar] [CrossRef]
- Cox, E.G.; Knoderer, C.A.; Jennings, A.; Brown, J.W.; Rodefeld, M.D.; Walker, S.G.; Turrentine, M.W. A randomized, controlled trial of catheter-related infectious event rates using antibiotic-impregnated catheters versus conventional catheters in pediatric cardiovascular surgery patients. J. Pediatr. Infect. Dis. Soc. 2013, 2, 67–70. [Google Scholar] [CrossRef]
- Jaworski, R.; Haponiuk, I.; Irga-Jaworska, N.; Chojnicki, M.; Steffens, M.; Paczkowski, K.; Zielinski, J. Fungal infections in children in the early postoperative period after cardiac surgery for congenital heart disease: A single-centre experience. Interact. Cardiovasc. Thorac. Surg. 2016, 23, 431–437. [Google Scholar] [CrossRef]
- de Araujo Motta, F.; Dalla-Costa, L.M.; Dominguez Muro, M.; Lenzi, A.; Picharski, G.L.; Burger, M. Risk Adjustment for Congenital Heart Surgery Score as a Risk Factor for Candidemia in Children Undergoing Congenital Heart Defect Surgery. Pediatr. Infect. Dis. J. 2016, 35, 1194–1198. [Google Scholar] [CrossRef]
- Bektaş, A.D.; Yasa, E.O.; Habip, Z.; Koçoğlu, E. Evaluation of risk factors in invasive Candida infections in children. J. Pediatr. Inf. 2023, 17, e151–e159. [Google Scholar] [CrossRef]
- Abdel-Hamid, R.M.; El-Mahallawy, H.A.; Abdelfattah, N.E.; Wassef, M.A. The impact of increasing non-albicans Candida trends on diagnostics in immunocompromised patients. Braz. J. Microbiol. 2023, 54, 2879–2892. [Google Scholar] [CrossRef] [PubMed]
- Arastehfar, A.; Hilmioğlu-Polat, S.; Daneshnia, F.; Pan, W.; Hafez, A.; Fang, W.; Liao, W.; Şahbudak-Bal, Z.; Metin, D.Y.; Júnior, J.N.A.; et al. Clonal Candidemia Outbreak by Candida parapsilosis Carrying Y132F in Turkey: Evolution of a Persisting Challenge. Front. Cell. Infect. Microbiol. 2021, 11, 676177. [Google Scholar] [CrossRef] [PubMed]
- Arikan-Akdagli, S.; Gülmez, D.; Doğan, Ö.; Çerikçioğlu, N.; Doluca Dereli, M.; Birinci, A.; Yıldıran, Ş.T.; Ener, B.; Öz, Y.; Metin, D.Y.; et al. First multicentre report of in vitro resistance rates in candidaemia isolates in Turkey. J. Glob. Antimicrob. Resist. 2019, 18, 230–234. [Google Scholar] [CrossRef] [PubMed]
- Castanheira, M.; Deshpande, L.M.; Messer, S.A.; Rhomberg, P.R.; Pfaller, M.A. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination. Int. J. Antimicrob. Agents 2020, 55, 105799. [Google Scholar] [CrossRef]
- Mesini, A.; Mikulska, M.; Giacobbe, D.R.; Del Puente, F.; Gandolfo, N.; Codda, G.; Orsi, A.; Tassinari, F.; Beltramini, S.; Marchese, A.; et al. Changing epidemiology of candidaemia: Increase in fluconazole-resistant Candida parapsilosis. Mycoses 2020, 63, 361–368. [Google Scholar] [CrossRef]
- Ağın, H.; Devrim, I.; İşgüder, R.; Karaarslan, U.; Kanık, E.; Günay, İ.; Kışla, M.; Aydın, S.; Gülfidan, G. Risk factors for candidemia in pediatric intensive care unit patients. Indian J. Pediatr. 2014, 81, 1158–1162. [Google Scholar] [CrossRef]
- de Paula Menezes, R.; de Oliveira Melo, S.G.; Bessa, M.A.; Silva, F.F.; Alves, P.G.; Araújo, L.B.; Penatti, M.P.; Abdallah, V.O.; von Dollinger de Brito Röder, D.; dos Santos Pedroso, R. Candidemia by Candida parapsilosis in a neonatal intensive care unit: Human and environmental reservoirs, virulence factors, and antifungal susceptibility. Braz. J. Microbiol. 2020, 51, 851–860. [Google Scholar] [CrossRef]
- Seagle, E.E.; Jackson, B.R.; Lockhart, S.R.; Georgacopoulos, O.; Nunnally, N.S.; Roland, J.; Barter, D.M.; Johnston, H.L.; Czaja, C.A.; Kayalioglu, H.; et al. The landscape of candidemia during the Coronavirus disease 2019 (COVID-19) pandemic. Clin. Infect. Dis. 2022, 74, 802–811. [Google Scholar] [CrossRef]
- Toda, M.; Williams, S.R.; Berkow, E.L.; Farley, M.M.; Harrison, L.H.; Bonner, L.; Marceaux, K.M.; Hollick, R.; Zhang, A.Y.; Schaffner, W.; et al. Population-Based Active Surveillance for Culture-Confirmed Candidemia—Four Sites, United States, 2012–2016. MMWR Surveill. Summ. 2019, 68, 1–15. [Google Scholar] [CrossRef]
- Poissy, J.; Damonti, L.; Bignon, A.; Khanna, N.; Von Kietzell, M.; Boggian, K.; Neofytos, D.; Vuotto, F.; Coiteux, V.; Artru, F.; et al. Risk factors for candidemia: A prospective matched case-control study. Crit. Care 2020, 24, 109. [Google Scholar] [CrossRef]
- Zhang, A.Y.; Shrum, S.; Williams, S.; Petnic, S.; Nadle, J.; Johnston, H.; Barter, D.; Vonbank, B.; Bonner, L.; Hollick, R.; et al. The Changing Epidemiology of Candidemia in the United States: Injection Drug Use as an Increasingly Common Risk Factor-Active Surveillance in Selected Sites, United States, 2014–2017. Clin. Infect. Dis. 2020, 71, 1732–1737. [Google Scholar] [CrossRef]
Variables | Candidemia (n = 36) | Control (n = 72) | p |
---|---|---|---|
Comorbidities | 9 (25) | 4 (5.5) | 0.015 |
Age, months | 4 (2–6) | 6 (3–9) | 0.680 |
Weight, kg | 5.1 (3–8) | 7.2 (6–8.4) | 0.040 |
Birth weight, kg | <0.001 | ||
≥2.5 | 24 (67) | 68 (94.5) | |
<2.5 | 12 (33) | 4 (5.5) | |
Male | 20 (55) | 38 (53) | 0.990 |
Single ventricle physiology | 14 (38.8) | 26 (36.1) | 0.990 |
Cyanotic heart disease | 21 (58.3) | 36 (50) | 0.860 |
Duration of preoperative mechanical ventilation, days | 2 (0–4) | 1 (0–2) | 0.990 |
CPB use | 33 (91.6) | 68 (94.5) | 0.900 |
CPB time, min | 80 (65–95) | 70 (60–80) | 0.450 |
RACHS-1 ≥ 4 | 18 (50) | 16 (22.2) | 0.01 |
Central venous catheter duration, days | 21 (15–28) | 7 (5–10) | <0.001 |
Thrombocytopenia (<100,000/mm3) at ICU admission | 20 (55.5) | 35 (48.6) | 0.780 |
Duration of postoperative mechanical ventilation, days | 14 (10–18) | 3 (1–5) | <0.001 |
TPN | 22 (61.1) | 11 (15.2) | <0.001 |
Duration of TPN, days | 10 (6–14) | 2 (1–3) | <0.001 |
ECMO | 4 (11.1) | - | <0.001 |
Arrhythmias | 3 (8.3) | 7 (9.7) | 0.810 |
Acute kidney injury | 6 (16.6) | 8 (11.1) | 0.540 |
LCOS | 11 (30.5) | 18 (25) | 0.990 |
Chylothorax | 7 (19.4) | 1 (1.3) | 0.001 |
Peritoneal dialysis | 6 (16.6) | 4 (5.5) | 0.03 |
Delayed sternal closure ≥2 days | 15 (41.6) | 5 (6.9) | <0.001 |
Prior bacteremia | 9 (25) | 6 (8.3) | 0.04 |
Candida colonization | 9 (25) | 1 (1.3) | 0.008 |
Any antimicrobial agent exposure | 33 (91.6) | 36 (50) | <0.001 |
Antimicrobial agents used ≥3 | 14 (38.8) | 5 (6.9) | <0.001 |
Cumulative antibiotic treatment duration | 10 (7–14) | 5 (3–7) | <0.001 |
Antifungal prophylaxis | 2 (5.5) | 1 (1.3) | 0.130 |
Use of corticosteroids | 7 (19.4) | 11 (15.2) | 0.870 |
ICU stay(days) | 28 (21–35) | 5 (3–7) | <0.001 |
Post-op hospital stay (days) | 40 (32–50) | 12 (8–14) | <0.001 |
Mortality | 22 (61.1) | 5 (6.9) | <0.001 |
Variables | p | Odds Ratio | 95% Confidence Interval |
---|---|---|---|
Birth weight < 2500 g | 0.02 | 3.2 | 2.5–5 |
RACHS-1 ≥ 4 | 0.01 | 2.1 | 1.3–6 |
Central venous catheter duration ≥14 days | <0.001 | 6.1 | 4–18 |
Mechanical ventilation dependency ≥10 days | 0.01 | 4.2 | 3–12 |
Total parenteral nutrition | <0.001 | 9 | 6–24 |
Cumulative antibiotic exposure for ≥7 days | <0.001 | 2.5 | 2–9 |
Delayed sternal closure ≥2 days | 0.04 | 1.8 | 1–4.5 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ozalp, O.; Ozturk, E. Candida Bloodstream Infections and Associated Risk Factors in Pediatric Cardiac Intensive Care. Diagnostics 2025, 15, 1001. https://doi.org/10.3390/diagnostics15081001
Ozalp O, Ozturk E. Candida Bloodstream Infections and Associated Risk Factors in Pediatric Cardiac Intensive Care. Diagnostics. 2025; 15(8):1001. https://doi.org/10.3390/diagnostics15081001
Chicago/Turabian StyleOzalp, Onur, and Erkut Ozturk. 2025. "Candida Bloodstream Infections and Associated Risk Factors in Pediatric Cardiac Intensive Care" Diagnostics 15, no. 8: 1001. https://doi.org/10.3390/diagnostics15081001
APA StyleOzalp, O., & Ozturk, E. (2025). Candida Bloodstream Infections and Associated Risk Factors in Pediatric Cardiac Intensive Care. Diagnostics, 15(8), 1001. https://doi.org/10.3390/diagnostics15081001